AFMD
NSDAffimed N.V.
Healthcare•Biotechnology
Watchlists:
Last updated: Tuesday 20th May 2025
0.18
-0.10 (-34.95%)
Prev Close:0.279
Open:0.2175
Bid:0.1936
Ask:0.2009
52 Week Range
0.078.95
Volume:15,298,098
Mkt Cap:2 M
35
MarketXLS Rank ®
Weak Hold
Price Target
$0.21
+15.7%
Financials
Financial Statements
AFMD - Cash Flow (Annual)
| Dec-23 | Dec-22 | Invalid date | |
|---|---|---|---|
| (increase) Decrease In Inventories | 100000.0 | -207000.0 | |
| (increase) Decrease In Other Current Assets | -4 M | ||
| (increase) Decrease In Payables | -10 M | -41 M | |
| (increase) Decrease In Receivables | 1 M | 2 M | |
| Capital Expenditure Reported | 4 M | 696000.0 | |
| Cash At Beginning Of Period | 190 M | 198 M | |
| Cash At End Of Period | 39 M | 194 M | |
| Cash Flow | -110 M | -103 M | |
| Cash Flow From Continuing Investing Activities | -36 M | 6 M | |
| Change In Account Payable | -10 M | -41 M | |
| Change In Payables And Accrued Expense | -10 M | -41 M | |
| Change In Working Capital | -12 M | -39 M | |
| Changes In Account Receivables | 1 M | 2 M | |
| Current Deferred Income Taxes | 3000.0 | 2000.0 | |
| Deferred Income Taxes | 2000.0 | ||
| Depreciation | 3 M | ||
| Depreciation Unreconciled | 2 M | 3 M | |
| Depreciation And Amortization | 2 M | 3 M | |
| Effect Of Exchange Rate Changes | 791000.0 | ||
| Financing Cash Flow | -6 M | 89 M | |
| Free Cash Flow | -114 M | -99 M | |
| Gain Loss On Sale Of Business | -4 M | ||
| Gain Loss On Sale Of PPE | 82000.0 | ||
| Issuance Of Capital Stock | 96 M | ||
| Issuance Of Capital Stock | 96 M | ||
| Issuance Of Debt | -6 M | ||
| Net Cash From Financing Activities | -6 M | 94 M | |
| Net Cash From Investing Activities | -36 M | 6 M | |
| Net Cash From Operating Activities | -110 M | -105 M | |
| Net Change In Cash & Cash Equivalents | -153 M | -11 M | |
| Net Income From Continuing Operations | -106 M | -85 M | |
| Net Business Purchase And Sale | 978000.0 | ||
| Net Capital Expenditure Disposals | -4 M | ||
| Net Common Stock Issuance | 96 M | ||
| Net Intangibles Purchase And Sale | -37000.0 | ||
| Net Issuance Payments Of Debt | -6 M | ||
| Net Long Term Debt Issuance | -6 M | ||
| Net PPE Purchase And Sale | -4 M | 6 M | |
| Operating (gains) Losses | -5 M | ||
| Other Financing Charges Net | -2 M | ||
| Other Investing Changes Net | -33 M | ||
| Other Non-cash Items | 11 M | 19 M | |
| Purchase Of Property Plant & Equipment | 6 M | ||
| Purchase Of Short Term Investments | 235000.0 | ||
| Purchase Of Intangibles | -37000.0 | ||
| Purchase Of PPE | -4 M | -659000.0 | |
| Repayment Of Debt | -6 M | ||
| Repayment Of Debt | -6 M | ||
| Sale Of Business | 978000.0 | ||
| Sale Of PPE | 6 M | ||
| Stock Based Compensation | 11 M | 19 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.